Estrella Immunopharma has appointed Cynthia Pussinen as Chief Executive Officer effective October 25, 2026. Ms. Pussinen succeeds Cheng Liu, Ph.D., who will take on the role of Chief Scientific Officer.
Who to call at Estrella Immunopharma, and when
A new leader at Estrella Immunopharma brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Estrella Immunopharma raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Estrella Immunopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Estrella Immunopharma. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Estrella Immunopharma
Location
California, United States
About
Estrella Immunopharma is a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Estrella Immunopharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CaliforniaBiotechnologyHealth CareTherapeuticsBiopharma